"we were quite surprised to find there were no significant differences," says study author.

yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital..

erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.